Kornimate/medical-research-clean huggingface dataset:
cryoneurolysis for cutaneous neuropathic pain

Conditions: Neuropathic Pain

Summary: feasibility study with 25 patients investigating the effect of cryoneurolysis on persistent cutaneous neuropathic pain after surgery and trauma. all patients receive active treatment (cryoneurolysis). the study design is unblinded, non-randomized, non-controlled.


Eligibility criteria:
inclusion criteria: * age \> 17 years * asa (american society of anesthesiologists) physical status classification system i-iii * informed consent * capable of subjective evaluation of pain * capable of reading and understanding danish and informed written consent * average pain intensity \>49/100 on vas in the primary focal pain area for a minimum of 6 months at the time of inclusion * relevant injury (surgery or trauma) of peripheral nerves * plausible cutaneous location of pain * in the area of pain, at least one of the following (1-8): (1) hypo/anesthesia for touch/brush (2) hypo/anesthesia for cold (3) hypo/anesthesia for warmth (4) hypo/anesthesia for pinprick (5) allodynia for touch/brush (6) allodynia for cold (7) allodynia for warmth (8) hyperalgesia for pinprick * neuropathic pain score (douleur neuropathique en 4 questions, dn-4) \>3/10 * definitive diagnosis of neuropathic pain (finnerup et al 2016) exclusion criteria: * inability to cooperate * inability to understand danish * allergy to local anesthetic * infection in the area of cryo probe insertion * significant competitive chronic pain * progressive neurologic disease * increased risk at needle insertion and cold exposure (e.g. raynaud, coagulopathies) * uncontrolled severe systemic disease * implanted electronic devices unless approved by the relevant medical specialist * previous cryoneurolysis with no relevant effect for the same neuropathic pain * previous interventional pain therapy (e.g. spinal cord stimulation) with no relevant effect for the same neuropathic pain * expected duration of life \< 2 years * pregnancy * abuse of alcohol, narcotics or medicine * current psychiatric disease * inclusion in other clinical trials * ongoing patient complaint * body mass index \ 34.9 kg/m2 * change of pain therapy within the last 28 days prior to inclusion
efficiency of physiotherapy treatments for low back pain in women.

Conditions: Low Back Pain

Summary: aim: to evaluate and compare the effectiveness of a combined treatment of tens or elec-tromagnetic and back school with the effectiveness of only the back school treatment. design: single-blind experimental prospective study of clinic intervention. setting: physiotherapy and speech therapy unit at the cambrils slight hospital. spain. population: 96 women (50-85 years) with chronic low back pathology. methods: subjects were divided into three randomized groups: back school (group 1), tens with back school (group 2), and magnetic therapy with back school (group 3). they have re-ceived 20 sessions of treatment. the intensity of pain (eva scale) and the quality of life (oswestry scale) were measured, at the beginning and at the end of the treatment and after three and six months. anthropometric and physical activity variables were collected.


Eligibility criteria:
inclusion criteria: * women between 50 and 85 years. * chronic lbp condition for at least three months ago. * patient's agreement by signing the consent. exclusion criteria: * cardiac pacemaker carriers. * patients with parts of osteosynthesis and / or prostheses. * patients with a not well balanced medical condition. * patients with tens at home and / or having completed physiotherapy during the last three months. * patients with skin infectious diseases or skin lesions and / or areas of hypoesthesia. * patients with malignant tumours. * patients who received any spinal injection during the last six weeks. * patients who participate or have participated in a study in the last three months
prospective study on covid -19 reinfection on vaccinated and non-vaccinated outpatients

Conditions: COVID-19 Pandemic

Summary: the aim of the study is to compare the severity of symptoms in case of reinfection with covid-19. the study will compare between two groups; vaccinated and non vaccinated. the side effects from vaccination and symptoms of infection and reinfection will be reprted.


Eligibility criteria:
inclusion criteria: * clinically diagnosed with covid infection * take any type of vaccines exclusion criteria: * no accept sharing * not vaccinated with covid vaccine
effect of subcutaneous polyvidone collagen treatment on hand recovery in adult rheumatoid arthritis.

Conditions: Arthritis, Rheumatoid

Summary: a study in geriatric rheumatology on the treatment of rheumatoid arthritis (ra) in older adults is described. its objective is to compare the effects of subcutaneous polyvidone collagen versus placebo, analyzing clinical improvement, biochemical response and quality of life in people over 60 years of age. the phase iv, double-blind, randomized, placebo-controlled clinical trial will be conducted between 2023 and 2026. sixty patients with early-stage arthritis will participate, assessing factors such as pain, functionality and synovitis with various statistical tools and analyses.

geriatric rheumatology specializes in the study of rheumatic diseases in older adults, who have immune and physiological characteristics that influence the manifestation of these diseases. in the case of rheumatoid arthritis (ra), a chronic inflammatory disease that affects the joints, treatments that improve functionality and reduce pain in the hands, evaluated by ultrasound, are studied. its objective is to compare the effects of treatment with subcutaneous polyvidone collagen versus placebo on clinical improvement of the hands, biochemical response and quality of life in people over 60 years of age with rheumatoid arthritis. a phase iv, double-blind, randomized, placebo-controlled clinical trial will be conducted between august 2023 and august 2026. sixty patients (30 in each group) with early-stage arthritis will participate. pain, functionality, synovitis, and quality of life will be assessed using various scales, biochemical analyses, and statistical tests.

Eligibility criteria:
inclusion criteria: * patients with arthritic hand uni or bilateral * early rheumatoid arthritis (\> or equal to 2 years of evolution with treatment and stable) * conventional treatment based on non-steroidal anti-inflammatory drugs (nsaids) alone for the disease without the use of biologic therapy or dmards. exclusion criteria: * patient with previous treatment of the arthritic hand with steroids, previous surgery and/or some other local medical treatment * persistence of symptoms and functional alterations. * patients with diabetes mellitus, rheumatic polyarthropathy, scleroderma, fibromyalgia, systemic lupus erythematosus or any other autoimmune disease.

Keywords: rheumatoid arthritis collagen polyvidone synovial tissue tumor necrosis factor-alpha american college of rheumatology questionnaire rheumatoid factor
rezūm vs. dual drug therapy for symptomatic benign prostatic hyperplasia in sexually active men

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: the study objective is to compare water vapor thermotherapy with the rezūm™ system to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.

study objective - to compare water vapor thermotherapy with the rezūm™ system to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men. study design - multicenter open-label randomized controlled parallel-group post-market trial. study treatments and randomization - subjects will be randomly assigned to rezūm or dual drug therapy treatments; 1:1 randomization via the electronic data capture (edc) system. both treatments are commercially available. subjects randomized to receive the rezūm treatment will receive standardized treatment and subjects randomized to dual drug therapy will receive the local formulary preferred choice of urinary selective alpha blocker and 5-alpha reductase inhibitor. visit schedule - study visits are at: enrollment/baseline, treatment, 3 months, 6 months, and yearly follow-up through 2 years.

Eligibility criteria:
inclusion criteria: 1. sexually active male subjects ≥ 45 years of age who have persistent non-neurogenic lower urinary tract symptoms refractory to first-line treatment with single agent alpha adrenoceptor antagonist therapy 2. subject is willing and able to answer all domains of mshq 3. completed ipss questionnaire with score ≥ 13 within 6 months prior to enrollment 4. peak urinary flow rate (qmax): ≤ 15 ml/sec with minimum voided volume of ≥ 150 ml within 6 months prior to enrollment 5. post-void residual (pvr) ≤250 ml within 6 months prior to enrollment 6. prostate volume ≥ 30 ml as measured by transrectal ultrasound or magnetic resonance imaging within 3 months prior to enrollment 7. subject is willing and capable of providing informed consent 8. subject is willing and capable of participating in all visits associated with this study at an approved clinical study site and at the intervals defined by this clinical investigational plan (cip) 9. france subjects only: subjects must be affiliated to national security insurance exclusion criteria: 1. inability to participate in full duration of study 2. prior surgical treatment for bph 3. increased risk of bleeding 4. presence of genitourinary cancer or other pelvic cancer 5. functional issues with bladder 6. presence of active infection in genitourinary tract 7. structural and anatomic issues with urinary tract and renal function 8. concomitant drug therapy 9. temporal restraints and risks for general anaesthesia or comorbidity that would elevate risk of participation

Keywords: prostate rezūm water vapor thermotherapy lower urinary tract symptoms bph luts
a study with aleglitazar in patients with a recent acute coronary syndrome and type 2 diabetes mellitus

Conditions: Diabetes Mellitus Type 2

Summary: this double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (acs) and type 2 diabetes mellitus. patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. the study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.


Eligibility criteria:
inclusion criteria: * adults \>18 years of age * type 2 diabetes mellitus * hospitalization for acs event and randomization between hospital discharge and 8 weeks after the acs index event (day of hospitalization) exclusion criteria: * estimated glomerular filtration rate \<45 ml/min/1.73m2 * concomitant treatment with a thiazolidinedione and/or fibrate * triglycerides \>400 mg/dl * anaemia * symptomatic congestive heart failure classified as new york heart association (nyha) class ii-iv (france and germany: symptomatic congestive heart failure classified as nyha class i-iv)
vinorelbine oral plus capecitabine combination in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: this study will evaluate the toxicity and secondary the efficacy of the combination vinorelbine plus capecitabine in metastatic breast cancer patients

the combination capecitabine-vinorelbine, with iv administration of vinorelbine, has been studied in a phase \[i\]/\[ii\], with favourable profile of toxicity in pretreated patients with anthracyclines and/or taxanes (oncology news international vol 12, no 3, suppl 2, 2003). in a study of toxicity and effectiveness, vanhopher reported objective response rates (pr) in 21 from 45 patients (47%) and stabilization of disease (sd) in 16 patients (36%). severe leucopenia (grade 4), was reported in 5% of patients (borquez d, et al: proc am soc clin oncol 19: abstract 420, 2000)

Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic breast cancer * age 18-75 years * bidimensionally measurable or evaluable disease * performance status (ps) 0-2 (ecog) * patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide, or surgical sterilization) during treatment and for three months after completing treatment * adequate liver (serum bilirubin \<1.5 times the upper normal limit, ast and alt \<2.5 times the unl in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases); adequate renal function (serum creatinine \<1.5 times the upper normal limit); and adequate bone marrow function(neutrophils ≥ 1.5x 109 /l, and platelets ≥ 100x 109 /l) * at least three weeks from completion of irradiation * life expectancy ≥ 12 weeks * patients able to take oral medication * written informed consent exclusion criteria: * active infection * brain metastases * history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * malnutrition (loss of ≥ 20% of the original body weight) * psychiatric illness or social situation that would preclude study compliance * pregnant or lactating women

Keywords: metastatic breast cancer vinorelbine oral capecitabine
providing resources to enhance patients' readiness to make decisions about kidney disease: the prepare now study

Conditions: Chronic Kidney Disease

Summary: this study evaluates the effectiveness of patient educational materials (a book and dvd) to help patients with chronic kidney disease make early, shared, and informed decisions about kidney replacement therapy. half of the participants will receive the educational materials and half will receive usual care from their doctors.

the investigators will study the effectiveness of patient educational materials (a book and dvd, called the prepared materials) to help patients with chronic kidney disease make early, shared, and informed decisions about kidney replacement therapy. half of the participants will receive the prepared materials and half will receive usual care from their doctors. prepared materials feature patients and their families discussing the pros and cons of different treatment options for kidney failure. the investigators will randomly assign patients already under the care of a nephrologist to receive the video and book or to receive their usual nephrology care. they will measure the degree to which patients in either study arm are prepared for kidney failure treatment at follow up.

Eligibility criteria:
inclusion criteria: * 18 years or older * english speaking * advanced kidney disease defined as an egfr \< 20 ml/min/1.73m2 at their last clinical appointment with their nephrologist * have not initiated a renal replacement therapy exclusion criteria: * cannot speak english * have initiated renal replacement therapy

Keywords: shared decision making patient education decision aids
hypertensive treatment pattern survey for type ii diabetes mellitus patients with complication and hypertension

Conditions: Hypertension

Summary: this study will address the treatment rate and control rate of hypertension, treatment pattern and factors to affect blood pressure control by examining (retrospective) medical records of type ii dm patients with dm related complication and hypertension, among outpatients coming to the endocrinology department in 20 general hospital settings nationwide.


Eligibility criteria:
inclusion criteria: * after diagnosed type ii dm, patients received treatment for a least 3 years * type ii dm patients with hypertension and its complication. * visited out-patients to care center after 1 jan. 2008 exclusion criteria: * secondary hypertension patients * patients not receiving hypertension medication * patients stopping bp medication, by physician's order * patients currently enrolled in other clinical studies

Keywords: hypertension type ii dm dm related complication jnc7 2007 esh-esc guidelines survey
effects of specified work site physical activity intervention among employees with physical heavy work

Conditions: Musculoskeletal Diseases

Summary: the purpose of this study is to evaluate the effect of specified worksite physical-activity interventions on musculoskeletal disorders in an industry with physical heavy workload.

studies regarding company adjusted intervention have shown positive effects regarding work related neck and shoulder symptoms among workers with monotonous repetitive work. however, limited research is available on physical exercise intervention among workers with physically heavy work. this study introduces a new intervention concept to treat and prevent musculoskeletal disorders including individually and health check based exercise intervention. the aim of this randomized controlled intervention project is 1. through health check to outline the extent musculoskeletal disability in workers with heavy work load in relation to physical and metabolic fitness. includes is also assessment of physical general activity and working conditions. 2. to evaluate the effect of individual adjusted exercise programs on muscle strength, aerobic capacity, musculoskeletal disability, pain, work ability and sick absenteeism

Eligibility criteria:
inclusion criteria: * constructions workers, working for more than 20 hours pr week, physical heavy work tasks (in danish: brolæggere, rørlæggere, mekanikere) exclusion criteria: * workers with flexible job i.e. for people with a reduced ability to work

Keywords: physical activity
polish multicenter perts pe outcomes registry

Conditions: Pulmonary Embolism With Acute Cor Pulmonale

Summary: pulmonary embolism (pe) is the third leading cause of cardiovascular mortality. the pulmonary embolism response team (pert) concept offers a rapid and multidisciplinary approach focused on improving outcomes for patients with pe. all institutionalized perts in poland have been invited to join the study. the goal of this registry is to describe current practice and outcomes in patients with acute pe treated by polish perts.

pulmonary embolism (pe) is the third leading cause of cardiovascular mortality. the presentation of pe may vary from asymptomatic or mild exertion disturbances (low-risk pe) treated with anticoagulants only to hemodynamic "obstructive" collapse and death (high-risk pe). patient outcome depends on ability of the right ventricle to sustain the increased afterload caused by the embolic burden. careful risk stratification is crucial, and the pulmonary embolism response team (pert) concept offers a rapid and multidisciplinary approach focused on improving outcomes for patients with pe by advancing its recognition, diagnosis, and treatment. all institutionalized perts in poland have been invited to join the study. the data is administrated by the poznan university of medical sciences on the basis of an agreement between the pert centres. the goal of this registry is to describe current practice and outcomes in patients with acute pe guided by polish perts. the primary data recorded include details of each patient's clinical status, co-morbidities, the administered treatment modalities, the results of additional studies (ab tests results, ecg, imaging studies), and the outcome. the data collection will have no impact on the way the patient is diagnosed and treated.the study endpoints comprise respiratory failure, shock, death distal systemic embolization (i.e. stroke) and major or minor bleeding complications classified according to the international society on thrombosis and haemostasis classification.

Eligibility criteria:
inclusion criteria: 1. pe confirmed by computed tomography pulmonary angiography. 2. pe symptoms duration ≤ 14 days. 3. high-risk pe with hemodynamic instability (one of): * cardiac arrest * obstructive shock * persistent hypotension. 4. intermediate-high risk pe patients with right ventricle dysfunction confirmed by imaging studies and elevated troponin level. exclusion criteria: 1. refusal to sign the informed consent form.

Keywords: pulmonary embolism, pulmonary embolism response team,
outcome after non-invasive ventilation.

Conditions: Respiratory Insufficiency

Summary: the study is an exploratory retrospective observational study with the aim to describe outcome fo the cohort of patients that receive non-invasive ventilation at an intensive care unit. main research questions are: * characteristics of the cohort. * the course for the patients at the icu. * icu-mortality and 30-day mortality * amount of patients with limitations of care. * factors associated with mortality.


Eligibility criteria:
inclusion criteria: * patients treated with non invasive ventilation * admitted to sundsvalls icu during 2018 exclusion criteria: * below 18 years age.

Keywords: non-invasive ventilation critical care
prospective study in noninvasive evaluation of hepatic fibrosis in chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the aim of our study is to evaluate liver fibrosis using biochemical markers, fibroscan, and radiology methods in patients with chronic hepatitis b in mainland china.

up to nov, 2015, total of 818 patients with chronic hbv infection had been enrolled in the study. paired blood and liver biopsy specimen had been collected. the serum samples stored at -80 degree celsius. all the liver biopsy samples were judged by three pathology experts, according to ishak standard.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic hepatitis b or compensated cirrhosis due to chronic hepatitis b virus infection * agree to have liver biopsy exclusion criteria: * clinical diagnosis of decompensated cirrhosis due to hepatitis b virus or inactive carrier * liver diseases due to other origin
lifestyle changes in pcos with osa and nafld

Conditions: PCOS; NAFLD; OSA

Summary: complain of obstructive sleeping apnea and fatty liver is common in pcos women so lifestyle changes are recommended

forty obese pcos men with obstructive sleeping apnea and compaint of fatty liver will participate in this trial . group (study group) will contain twenty obese females with a complaint of pcos and osa and fatty liver. for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake, and daily walking for 30 minutes. group (control group) will contain twenty obese females with a complaint of pcos and osa and fatty liver . for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake,

Eligibility criteria:
inclusion criteria: * forty women * women complaint pcos * women complain obstructive sleep apnea * women are obese * women complain fatty liver exclusion criteria: * cardiac insult * renal insult * malignacy * pregnancy